PMID- 12537664
OWN - NLM
STAT- MEDLINE
DCOM- 20030605
LR  - 20061115
IS  - 1084-9785 (Print)
IS  - 1084-9785 (Linking)
VI  - 17
IP  - 6
DP  - 2002 Dec
TI  - Advances in dendritic cell-based vaccine of cancer.
PG  - 601-19
AB  - Dendritic cells (DCs) are potent antigen presenting cells that exist in virtually 
      every tissue, and from which they capture antigens and migrate to secondary 
      lymphoid organs where they activate naive T cells. Although DCs are normally 
      present in extremely small numbers in the circulation, recent advances in DC 
      biology have allowed the development of methods to generate large numbers of 
      these cells in vitro. Because of their immunoregulatory capacity, vaccination 
      with tumor antigen-presenting DCs has been proposed as a treatment modality for 
      cancer. In animal models, vaccination with DCs pulsed with tumor peptides, 
      lysates, or RNA or loaded with apoptotic/necrotic tumor cells could induce 
      significant antitumor CTL responses and antitumor immunity. However, the results 
      from early clinical trails pointed to a need for additional improvement of 
      DC-based vaccines before they could be considered as practical alternatives to 
      the existing cancer treatment strategies. In this regard, subsequent studies have 
      shown that DCs that express transgenes encoding tumor antigens are more potent 
      primers of antitumor immunity both in vitro and in vivo than DCs simply pulsed 
      with tumor peptides. Furthermore, DCs that have been engineered to express 
      certain cytokines or chemokines can display a substantially improved maturation 
      status, capacity to migrate to secondary lymphoid organs in vivo, and abilities 
      to stimulate tumor-specific T cell responses and induce tumor immunity in vivo. 
      In this review we also discuss a number of factors that are important 
      considerations in designing DC vaccine strategies, including (i) the type and 
      concentrations of tumor peptides used for pulsing DCs; (ii) the timing and 
      intervals for DC vaccination/boostable data on DC vaccination portends bright 
      prospects for this approach to tumor immune therapy, either alone or in 
      conjunction with other therapies.
FAU - Zhang, Xueshu
AU  - Zhang X
AD  - Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department 
      of Oncology, Saskatoon, Saskatchewan, Canada.
FAU - Gordon, John R
AU  - Gordon JR
FAU - Xiang, Jim
AU  - Xiang J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (RNA, Messenger)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Apoptosis
MH  - CD40 Ligand/genetics
MH  - Cancer Vaccines/*immunology
MH  - Dendritic Cells/*immunology/metabolism
MH  - Genetic Engineering
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/genetics
MH  - Humans
MH  - Neoplasms/immunology/*therapy
MH  - RNA, Messenger/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Transfection
MH  - Vaccination
RF  - 168
EDAT- 2003/01/23 04:00
MHDA- 2003/06/06 05:00
CRDT- 2003/01/23 04:00
PHST- 2003/01/23 04:00 [pubmed]
PHST- 2003/06/06 05:00 [medline]
PHST- 2003/01/23 04:00 [entrez]
AID - 10.1089/108497802320970217 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2002 Dec;17(6):601-19. doi: 
      10.1089/108497802320970217.